Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New eczema drug shows promise in Mid-Stage trial

NCT ID NCT07037901

Disease control Sponsor: Inmagene LLC Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 13, 2026 · Updated 2 times

Summary

This study tests whether IMG-007 can safely reduce eczema symptoms like itching and redness in adults with moderate-to-severe disease who haven't responded well to topical treatments. About 405 participants will receive either the drug or a placebo, and researchers will measure skin improvement over 24 weeks. The goal is to find the best dose for controlling this chronic skin condition.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 405 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2025

Expected to finish

Aug 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 74 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Inclusion Criteria: * Moderate-to-severe AD * Documented history of inadequate response or lack of tolerability to a stable regimen of one or more topical treatment before the Screening visit, or for whom topical treatments are otherwise inadvisable * Female participants who are not pregnant or breastfeeding and meet at least one of the following conditions: not of childbearing potential or of childbearing potential and agrees to use a highly effective method of contraception * Male participants must agree to use a highly effective method of contraception * EASI score ≥16 * vIGA-AD score ≥3 * ≥10% body surface area (BSA) of AD involvement * Mean peak pruritus numerical rating scale ≥ 4 during 7-days before randomization Key Exclusion Criteria: * Positive hepatitis B, hepatitis C, or human immunodeficiency virus infection * Evidence of active or latent tuberculosis (TB) * History of untreated or inadequately treated TB infection * Active infection requiring treatment with systemic antibiotics, antivirals, antifungals, antiparasitics or antiprotozoals * Active unstable pruritic skin conditions in addition to AD that would interfere with the assessment of AD based on the investigator's clinical judgement * Other conditions or laboratory abnormality that could increase the risk associated with study participation or could interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into the study * Having received any of the specified therapies within the specified timeframe(s) prior to the Baseline visit

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atopic dermatitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atopic eczema dermatitis Eczema immune system disorder skin disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atopic dermatitis Atopic dermatitis (eczema) Eczema

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    30 sites in 4 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Inmagene Site 1

    RECRUITING

    Lancaster, California, 93534, United States

  • Inmagene Site 10

    RECRUITING

    Fargo, North Dakota, 58103, United States

  • Inmagene Site 11

    RECRUITING

    Woodbury, New York, 11797, United States

  • Inmagene Site 12

    RECRUITING

    Anderson, South Carolina, 29621, United States

  • Inmagene Site 13

    RECRUITING

    Mississauga, Ontario, L4Y 4C5, Canada

  • Inmagene Site 14

    RECRUITING

    Montreal, Quebec, H2X 2V1, Canada

  • Inmagene Site 15

    RECRUITING

    Surrey, British Columbia, V3R 6A7, Canada

  • Inmagene Site 16

    RECRUITING

    Saskatoon, Saskatchewan, S7K 2C1, Canada

  • Inmagene Site 17

    RECRUITING

    Greater Sudbury, Ontario, P3C 1X8, Canada

  • Inmagene Site 18

    RECRUITING

    North Bay, Ontario, P1B 3Z7, Canada

  • Inmagene Site 19

    RECRUITING

    Ocala, Florida, 34470, United States

  • Inmagene Site 2

    RECRUITING

    Rolling Meadows, Illinois, 60008, United States

  • Inmagene Site 20

    RECRUITING

    Charlotte, North Carolina, 28277, United States

  • Inmagene Site 21

    RECRUITING

    New York, New York, 10029, United States

  • Inmagene Site 22

    RECRUITING

    Vancouver, British Columbia, V6H 4B1, Canada

  • Inmagene Site 23

    RECRUITING

    Los Angeles, California, 90095, United States

  • Inmagene Site 24

    NOT_YET_RECRUITING

    Mitcham, Victoria, 3132, Australia

  • Inmagene Site 25

    NOT_YET_RECRUITING

    Woden, Australian Capital Territory, 2606, Australia

  • Inmagene Site 26

    NOT_YET_RECRUITING

    Benowa, Queensland, 4217, Australia

  • Inmagene Site 27

    NOT_YET_RECRUITING

    Carlton, Victoria, 3053, Australia

  • Inmagene Site 28

    NOT_YET_RECRUITING

    Liverpool, New South Wales, 2170, Australia

  • Inmagene Site 29

    NOT_YET_RECRUITING

    Hamilton, Waikato Region, 3204, New Zealand

  • Inmagene Site 3

    RECRUITING

    Portland, Oregon, 97210, United States

  • Inmagene Site 30

    NOT_YET_RECRUITING

    Auckland, 1051, New Zealand

  • Inmagene Site 4

    RECRUITING

    Tampa, Florida, 33609, United States

  • Inmagene Site 5

    RECRUITING

    Mayfield Heights, Ohio, 44124, United States

  • Inmagene Site 6

    RECRUITING

    Kew Gardens, New York, 11415, United States

  • Inmagene Site 7

    RECRUITING

    Burien, Washington, 698168, United States

  • Inmagene Site 8

    RECRUITING

    Southlake, Texas, 76092, United States

  • Inmagene Site 9

    RECRUITING

    Columbus, Ohio, 43213, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.